RichardMauryStoneMD

PubMed

• 1 citations
  Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
  Andrew Stiff, Maarten Fornerod, Bailee N Kain, Deedra Nicolet, Benjamin J Kelly
  Nature Genetics. 2024-11-01
• White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia age...
  Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J Walker, James S Blachly
  American Journal of Hematology. 2024-11-01
• Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
  Marlise R Luskin, Mark Alan Murakami, Julia H Keating, Yael Flamand, Eric S Winer
  Blood. 2024-10-07

Journal Articles

• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome  
  Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature

Abstracts/Posters

• Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled Trial
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults
  Richard Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patient...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Int...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)
  Richard Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
  Richard Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of th...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leuke...
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Sleep Disturbance Among Patients with Myelodysplastic Syndromes and Acute Leukemia
  Richard Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
  Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed mutated AML. 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
• Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Pre... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutations in Genes Associated with Familial Predisposition to Myeloid Neoplasms: Their Frequency and Associations with Pretreatment Characteristics in Adult Patients (... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Rando... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Genome-Wide Association Study (GWAS) Identifies a Significant Acute Myeloid Leukemia (AML) Susceptibility Locus Near BICRA 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with N... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid L... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical, Immunophenotypic and Genomic Findings  of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Novel Therapies for AML: Expanding Future Options 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• The Changing Game Plan for Acute Lymphocytic Leukemia: Emerging Treatment Options and Progressive Approaches to Patient Care 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all

Other

• Older Adults with Acute Myeloid Leukemia Treated with Intensive Chemotherapy: “Old” Prognostic Algorithms May Not Apply 
  Richard Stone, MD, Haematologica
  https://www.doximity.com/articles/b27bba2a-b21b-4ce6-8922-56d9b6b9b894
  UpToDate, Wolters Kluwer Health - 2013-04-10